Adjunctive corticosteroid therapy might cut back the danger of demise amongst sufferers with tuberculous meningitis (TBM), with findings suggesting a very favorable impact with dexamethasone, based on research outcomes revealed in Mind and Conduct.
As a extreme, life-threatening neurologic complication of Mycobacterium tuberculosis an infection, TBM carries substantial mortality regardless of anti-tuberculosis remedy. Corticosteroids are generally added to therapy to regulate the inflammatory response related to TBM, however questions stay about their results on survival and problems throughout completely different affected person populations.
Researchers carried out a scientific evaluate, meta-analysis, and meta-regression to guage the efficacy and security of adjunctive corticosteroid remedy in sufferers with TBM. They searched a number of databases for randomized and quasi-randomized managed trials revealed by way of Might 2025. Eligible research enrolled sufferers with TBM who acquired adjunctive corticosteroids plus normal anti-tuberculosis therapy and included a placebo or standard-treatment comparator group.
[T]hese knowledge reinforce the present therapy tips of the world and justify the additional software of corticosteroids as one of many adjunctive therapies to deal with TBM, however with strict warning in immunocompromised sufferers.
The first end result was all-cause mortality. Secondary outcomes included gastrointestinal bleeding, visible and auditory impairment, hydrocephalus, and joint problems. The researchers additionally examined whether or not outcomes differed based on corticosteroid sort, HIV standing, and the revenue classification of the nation by which the research was carried out.
Total, 11 trials involving 1917 sufferers have been included within the closing evaluation, with 985 sufferers receiving adjunctive corticosteroids and 932 receiving normal anti-tuberculosis remedy. The research enrolled each pediatric and grownup populations, with ages starting from infancy to older than 45 years. Particular person trials included 23 to 531 members, and follow-up ranged from 1 month to 2 years. Research have been carried out in international locations together with Vietnam, India, Egypt, Thailand, South Africa, and China.
Dexamethasone was evaluated in 5 trials and was essentially the most ceaselessly studied corticosteroid. Different corticosteroids included prednisolone, methylprednisolone, and hydrocortisone. Illness severity was generally labeled utilizing British Medical Analysis Council grades I by way of III.
9 trials with 1747 sufferers contributed to the evaluation of all-cause mortality. In contrast with normal anti-tuberculosis remedy alone, adjunctive corticosteroids have been related to a 16% decrease danger of demise (pooled danger ratio [RR], 0.84; 95% CI, 0.76-0.94; P =.002). There was no important between-study heterogeneity (I²=0%), and the proof supporting the mortality discovering was rated as excessive certainty.
When outcomes have been assessed based on corticosteroid sort, dexamethasone was related to a major discount in mortality (RR, 0.87; 95% CI, 0.77-0.97). The evaluation additionally instructed a larger survival profit amongst sufferers who acquired care in lower-income settings.
HIV standing appeared to affect the therapy impact. Amongst sufferers with HIV, corticosteroid therapy was not considerably related to decrease mortality (RR, 0.90; 95% CI, 0.77-1.05; P =.18). This discovering is in line with the big 2023 Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-Contaminated Adults trial (ACT HIV; ClinicalTrials.gov Identifier: NCT03092817) included into the meta-analysis, which didn’t reveal a survival benefit with adjunctive dexamethasone amongst adults with HIV-associated TBM.
The mortality findings weren’t defined by variations in follow-up length (β, 0.3697; P =.5432). Outcomes additionally remained important after trials at excessive danger of bias have been eliminated (RR, 0.84; 95% CI, 0.73-0.97; P =.02), and excluding research revealed earlier than 2000 didn’t materially change the general findings.
No important variations between therapy teams have been reported for gastrointestinal bleeding (RR, 0.87; 95% CI, 0.44-1.75; P =.71), visible impairment (RR, 1.62; 95% CI, 0.76-3.46; P =.21), auditory impairment (RR, 0.79; 95% CI, 0.36-1.73; P =.55), hydrocephalus (RR, 0.47; 95% CI, 0.09-2.34; P =.36), or joint problems (RR, 0.63; 95% CI, 0.26-1.50; P =.30).
Examine limitations embrace variations in corticosteroid regimens throughout trials, incomplete reporting of HIV standing and baseline TBM severity, decreased illustration of youngsters and sufferers with HIV, and variability in end result evaluation amongst older research.
“[T]hese knowledge reinforce the present therapy tips of the world and justify the additional software of corticosteroids as one of many adjunctive therapies to deal with TBM, however with strict warning in immunocompromised sufferers,” the researchers concluded.
